Q2/FY2022 FINANCIAL RESULTS
ENDED SEPTEMBER 30, 2022

from the beginning

Q2/FY2022 FINANCIAL RESULTSENDED SEPTEMBER 30, 2022

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

Q2/FY2022 Consolidated Financial Results
FY2022 Revised Forecasts

• Q2/FY2022 FINANCIAL RESULTS: OVERVIEW

• Q2/FY2022 FINANCIAL RESULTS

• Q2/FY2022 FINANCIAL RESULTS & OUTLOOK: XTANDI

• Q2/FY2022 FINANCIAL RESULTS & OUTLOOK: STRATEGIC PRODUCTS

• Q2/FY2022 FINANCIAL RESULTS: COST ITEMS

• FY2022 REVISED FORECAST

Initiatives for Sustainable Growth

• XTANDI & STRATEGIC PRODUCTS: KEY EVENTS EXPECTED IN FY2022

• FEZOLINETANT: KEY SUCCESS FACTORS AND LATEST STATUS IN US AND EUROPE

• PROGRESS IN FOCUS AREA APPROACH (1/4): CURRENT STATUS OF PROJECTS IN CLINICAL TRIAL

• PROGRESS IN FOCUS AREA APPROACH (2/4): NEW PRIMARY FOCUS“TARGETED PROTEIN DEGRADATION”(1)

• PROGRESS IN FOCUS AREA APPROACH (3/4): NEW PRIMARY FOCUS“TARGETED PROTEIN DEGRADATION”(2)

• PROGRESS IN FOCUS AREA APPROACH (4/4): STRATEGIC INVESTMENT WITH TAYSHA GENE THERAPIES

• PROGRESS TOWARD ACHIEVING CSP2021

• UPCOMING EVENT

APPENDIX

• CHANGE EXCHANGE RATES USED FOR ELIMINATION OF UNREALIZED PROFIT ON INVENTORIES

• CHANGE EXCHANGE RATES USED FOR ELIMINATION OF UNREALIZED PROFIT ON INVENTORIES（PRO FORMA FIGURES）

• Q2/FY2022: REVENUE BY REGION

• Q2/FY2022: SALES OF MAIN PRODUCTS

• Q2/FY2022 ACTUAL: FX RATE

• FY2022 FCST: FXRATE & FXSENSITIVITY

• BALANCESHEET & CASHFLOWHIGHLIGHTS

• CAPITAL ALLOCATION

• ROBUST PIPELINE OF ASTELLAS

• PROGRESS IN OVERALL PIPELINE

• XTANDI & STRATEGIC PRODUCTS: STATUS UPDATE

• ENZALUTAMIDE (1/2): ANDROGEN RECEPTOR INHIBITOR

• ENZALUTAMIDE (2/2): PHASE 3 STUDY DATA BY DISEASE STAGE

• ENFORTUMAB VEDOTIN (EV) (1/4): NECTIN-4 TARGETED ADCOVERALL UC PROGRAM

• ENFORTUMAB VEDOTIN (EV) (2/4): CLINICAL STUDIES

• ENFORTUMAB VEDOTIN (EV) (3/4): STUDY DATA BY DISEASE STAGE OF UC

• ENFORTUMAB VEDOTIN (EV) (4/4): FUTURE OUTLOOK

• GILTERITINIB: FLT3 INHIBITOR

• ZOLBETUXIMAB: ANTI-CLAUDIN 18.2 MONOCLONAL ANTIBODY

• FEZOLINETANT: NK3 RECEPTOR ANTAGONIST

• AT132 (RESAMIRIGENE BILPARVOVEC): rAAV8-Des-hMTM1

• FOCUS AREA APPROACH:CLINICAL PROOF AND EXPANSION OF KEY PLATFORMS

• PROGRESS IN Rx+ PROGRAM

• ON THE FOREFRONT OF HEALTHCARE CHANGE

Questions

• Questions 1

• Questions 2

• Questions 3

• Questions 4

• Questions 5

• Questions 6

• Questions 7

• Questions 8

• Questions 9

• Questions 10